Protective	O
and	O
therapeutic	O
role	O
of	O
2	O
-	O
carba	O
-	O
cyclic	O
phosphatidic	O
acid	O
in	O
demyelinating	B-DS
disease	I-DS

Background	O

Multiple	B-DS
sclerosis	I-DS
is	O
a	O
neuroinflammatory	O
demyelinating	O
and	O
neurodegenerative	B-DS
disease	I-DS
of	O
the	O
central	O
nervous	O
system	O
characterized	O
by	O
recurrent	O
and	O
progressive	O
demyelination	B-DS
/	O
remyelination	O
cycles	O
,	O
neuroinflammation	O
,	O
oligodendrocyte	O
loss	O
,	O
demyelination	B-DS
,	O
and	O
axonal	O
degeneration	O
.	O

Cyclic	O
phosphatidic	O
acid	O
(	O
cPA	O
)	O
is	O
a	O
natural	O
phospholipid	O
mediator	O
with	O
a	O
unique	O
cyclic	O
phosphate	O
ring	O
structure	O
at	O
the	O
sn	O
-	O
2	O
and	O
sn	O
-	O
3	O
positions	O
of	O
the	O
glycerol	O
backbone	O
.	O

We	O
reported	O
earlier	O
that	O
cPA	O
elicits	O
a	O
neurotrophin	B-GP
-	O
like	O
action	O
and	O
protects	O
hippocampal	O
neurons	O
from	O
ischemia	O
-	O
induced	O
delayed	O
neuronal	O
death	O
.	O

We	O
designed	O
,	O
chemically	O
synthesized	O
,	O
and	O
metabolically	O
stabilized	O
derivatives	O
of	O
cPA	O
:	O
2	O
-	O
carba	O
-	O
cPA	O
(	O
2ccPA	O
),	O
a	O
synthesized	O
compound	O
in	O
which	O
one	O
of	O
the	O
phosphate	O
oxygen	O
molecules	O
is	O
replaced	O
with	O
a	O
methylene	O
group	O
at	O
the	O
sn	O
-	O
2	O
position	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
2ccPA	O
exerts	O
protective	O
effects	O
in	O
oligodendrocytes	O
and	O
suppresses	O
pathology	O
in	O
the	O
two	O
most	O
common	O
mouse	B-OG
models	O
of	O
multiple	B-DS
sclerosis	I-DS
.	O

Methods	O

To	O
evaluate	O
whether	O
2ccPA	O
has	O
potential	O
beneficial	O
effects	O
on	O
the	O
pathology	O
of	O
multiple	B-DS
sclerosis	I-DS
,	O
we	O
investigated	O
the	O
effects	O
of	O
2ccPA	O
on	O
oligodendrocyte	O
cell	O
death	O
in	O
vitro	O
and	O
administrated	O
2ccPA	O
to	O
mouse	B-OG
models	O
of	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
(	O
EAE	B-DS
)	O
and	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
.	O

Results	O

We	O
demonstrated	O
that	O
2ccPA	O
suppressed	O
the	O
CoCl2	O
-	O
induced	O
increase	O
in	O
the	O
Bax	B-GP
/	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	O
expression	O
ratio	O
and	O
phosphorylation	O
levels	O
of	O
p38MAPK	B-GP
and	O
JNK	B-GP
protein	O
.	O

2ccPA	O
treatment	O
reduced	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
,	O
microglial	O
activation	O
,	O
NLRP3	B-GP
inflammasome	O
,	O
and	O
motor	O
dysfunction	O
.	O

Furthermore	O
,	O
2ccPA	O
treatment	O
reduced	O
autoreactive	O
T	O
cells	O
and	O
macrophages	O
,	O
spinal	B-DS
cord	I-DS
injury	I-DS
,	O
and	O
pathological	O
scores	O
in	O
EAE	B-DS
,	O
the	O
autoimmune	O
multiple	B-DS
sclerosis	I-DS
mouse	B-OG
model	O
.	O

Conclusions	O

We	O
demonstrated	O
that	O
2ccPA	O
protected	O
oligodendrocytes	O
via	O
suppression	O
of	O
the	O
mitochondrial	O
apoptosis	O
pathway	O
.	O

Also	O
,	O
we	O
found	O
beneficial	O
effects	O
of	O
2ccPA	O
in	O
the	O
multiperiod	O
of	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
and	O
the	O
pathology	O
of	O
EAE	B-DS
.	O

These	O
data	O
indicate	O
that	O
2ccPA	O
may	O
be	O
a	O
promising	O
compound	O
for	O
the	O
development	O
of	O
new	O
drugs	O
to	O
treat	O
demyelinating	B-DS
disease	I-DS
and	O
ameliorate	O
the	O
symptoms	O
of	O
multiple	B-DS
sclerosis	I-DS
.	O

Background	O

Multiple	B-DS
sclerosis	I-DS
is	O
an	O
inflammatory	O
demyelinating	O
and	O
neurodegenerative	B-DS
disease	I-DS
of	O
the	O
CNS	O
characterized	O
by	O
recurrent	O
and	O
progressive	O
demyelination	B-DS
/	O
remyelination	O
cycles	O
,	O
neuroinflammation	O
,	O
oligodendrocyte	O
loss	O
,	O
demyelination	B-DS
,	O
and	O
axonal	O
degeneration	O
[	O
1	O
–	O
3	O
].	O

In	O
multiple	B-DS
sclerosis	I-DS
,	O
oligodendrocytes	O
are	O
the	O
target	O
of	O
inflammatory	O
attacks	O
and	O
their	O
cell	O
death	O
mediated	O
by	O
activated	O
lymphocytes	O
,	O
macrophages	O
,	O
and	O
glial	O
activation	O
results	O
in	O
axonal	O
demyelination	B-DS
.	O

Since	O
myelin	O
-	O
forming	O
oligodendrocytes	O
provide	O
critical	O
support	O
to	O
the	O
neuronal	O
axon	O
,	O
demyelination	B-DS
results	O
in	O
diverse	O
neurological	O
symptoms	O
determined	O
by	O
the	O
functions	O
of	O
affected	O
neurons	O
.	O

Therefore	O
,	O
therapies	O
designed	O
to	O
protect	O
oligodendrocytes	O
and	O
myelin	O
during	O
neuroinflammation	O
are	O
important	O
strategies	O
to	O
halt	O
the	O
progression	O
of	O
multiple	B-DS
sclerosis	I-DS
.	O

The	O
most	O
commonly	O
studied	O
animal	B-OG
models	O
of	O
multiple	B-DS
sclerosis	I-DS
are	O
the	O
autoimmune	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
(	O
EAE	B-DS
)	O
model	O
[	O
4	O
,	O
5	O
]	O
and	O
the	O
cuprizone	O
(	O
bis	O
-	O
cyclohexanone	O
-	O
oxalyldihydrazone	O
,	O
CPZ	O
)-	O
induced	O
demyelination	B-DS
model	O
[	O
6	O
,	O
7	O
].	O

Extensive	O
research	O
regarding	O
the	O
detailed	O
mechanisms	O
underlying	O
immune	O
-	O
mediated	O
demyelination	B-DS
in	O
multiple	B-DS
sclerosis	I-DS
has	O
been	O
conducted	O
using	O
EAE	B-DS
model	O
mice	B-OG
[	O
4	O
,	O
5	O
].	O

Activated	O
autoreactive	O
T	O
cells	O
proliferate	O
and	O
release	O
cytokines	B-GP
,	O
which	O
disrupt	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
and	O
secrete	O
chemokines	B-GP
that	O
lead	O
to	O
the	O
recruitment	O
of	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
macrophages	O
.	O

Infiltrated	O
immune	O
cells	O
secrete	O
autoantibodies	O
against	O
the	O
myelin	O
sheath	O
,	O
ultimately	O
resulting	O
in	O
myelin	O
degeneration	O
[	O
8	O
].	O

The	O
cuprizone	O
model	O
is	O
characterized	O
by	O
the	O
apoptotic	O
death	O
of	O
mature	O
oligodendrocytes	O
[	O
7	O
]	O
and	O
is	O
accompanied	O
by	O
neuroinflammation	O
and	O
motor	O
dysfunction	O
[	O
9	O
].	O

The	O
model	O
is	O
used	O
to	O
study	O
processes	O
of	O
demyelination	B-DS
and	O
remyelination	O
in	O
the	O
CNS	O
.	O

Primary	O
oligodendrocyte	O
apoptosis	O
in	O
connection	O
with	O
microglial	O
activation	O
are	O
the	O
major	O
histopathological	O
hallmarks	O
of	O
the	O
cuprizone	O
animal	B-OG
model	O
.	O

These	O
pathological	O
features	O
are	O
also	O
characteristics	O
of	O
lesion	O
formation	O
in	O
human	B-OG
multiple	B-DS
sclerosis	I-DS
[	O
10	O
].	O

Mitochondrial	O
dysfunction	O
is	O
also	O
an	O
important	O
component	O
of	O
human	B-OG
multiple	B-DS
sclerosis	I-DS
lesions	O
and	O
plays	O
a	O
key	O
role	O
in	O
the	O
loss	O
of	O
oligodendrocytes	O
and	O
axons	O
,	O
which	O
can	O
be	O
observed	O
in	O
both	O
the	O
EAE	B-DS
and	O
cuprizone	O
models	O
.	O

Cyclic	O
phosphatidic	O
acid	O
(	O
cPA	O
)	O
is	O
a	O
natural	O
phospholipid	O
mediator	O
with	O
a	O
unique	O
cyclic	O
phosphate	O
ring	O
structure	O
at	O
the	O
sn	O
-	O
2	O
and	O
sn	O
-	O
3	O
positions	O
of	O
the	O
glycerol	O
backbone	O
.	O

cPA	O
elicits	O
a	O
neurotrophin	B-GP
-	O
like	O
action	O
[	O
11	O
]	O
and	O
protects	O
neurons	O
from	O
mitochondrial	O
dysfunction	O
-	O
induced	O
apoptosis	O
[	O
12	O
]	O
and	O
ischemia	O
-	O
induced	O
delayed	O
neuronal	O
death	O
[	O
13	O
].	O

We	O
have	O
also	O
reported	O
previously	O
that	O
cPA	O
suppresses	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
and	O
motor	O
dysfunction	O
[	O
14	O
].	O

We	O
designed	O
,	O
chemically	O
synthesized	O
,	O
and	O
metabolically	O
stabilized	O
derivatives	O
of	O
cPA	O
:	O
2	O
-	O
carba	O
-	O
cPA	O
(	O
2ccPA	O
),	O
a	O
synthesized	O
compound	O
in	O
which	O
one	O
of	O
the	O
phosphate	O
oxygen	O
molecules	O
is	O
replaced	O
with	O
a	O
methylene	O
group	O
at	O
the	O
sn	O
-	O
2	O
position	O
;	O
this	O
showed	O
much	O
more	O
potent	O
biological	O
activity	O
than	O
natural	O
cPA	O
[	O
15	O
–	O
17	O
].	O

Our	O
preliminary	O
experiments	O
revealed	O
that	O
2ccPA	O
was	O
detected	O
in	O
the	O
mouse	B-OG
brain	O
following	O
intraperitoneal	O
administration	O
.	O

Based	O
on	O
this	O
finding	O
,	O
we	O
speculated	O
that	O
circulated	O
2ccPA	O
may	O
gain	O
access	O
to	O
the	O
brain	O
via	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Currently	O
,	O
we	O
are	O
investigating	O
the	O
pharmacokinetics	O
of	O
2ccPA	O
in	O
a	O
separate	O
study	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
2ccPA	O
exerts	O
protective	O
effects	O
in	O
oligodendrocytes	O
and	O
suppresses	O
pathology	O
in	O
EAE	B-DS
and	O
cuprizone	O
-	O
induced	O
mouse	B-OG
models	O
of	O
multiple	B-DS
sclerosis	I-DS
.	O

We	O
demonstrated	O
that	O
2ccPA	O
protected	O
oligodendrocytes	O
via	O
suppression	O
of	O
the	O
mitochondrial	O
apoptosis	O
pathway	O
,	O
suppressed	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
and	O
motor	O
dysfunction	O
,	O
and	O
attenuated	O
the	O
clinical	O
symptoms	O
of	O
EAE	B-DS
.	O

Methods	O

Pharmacologic	O
agents	O

2	O
-	O
Carba	O
-	O
cPA	O
(	O
2ccPA	O
)	O
was	O
chemically	O
synthesized	O
as	O
previously	O
described	O
(	O
Fig	O
.	O
2a	O
)	O
[	O
16	O
,	O
18	O
].	O

For	O
in	O
vivo	O
experiments	O
,	O
2ccPA	O
was	O
dissolved	O
in	O
saline	O
(	O
vehicle	O
).	O

For	O
in	O
vitro	O
experiments	O
,	O
2ccPA	O
was	O
dissolved	O
in	O
phosphatase	B-GP
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
containing	O
0	O
.	O
1	O
%	O
fatty	O
acid	O
-	O
free	O
bovine	O
serum	O
albumin	B-GP
(	O
BSA	O
)	O
(	O
vehicle	O
).	O

Cell	O
culture	O
and	O
treatments	O

The	O
MO3	O
.	O
13	O
cell	O
line	O
(	O
CELLutions	O
Biosystems	O
,	O
Inc	O
.)	O
is	O
an	O
immortalized	O
human	B-OG
-	O
human	B-OG
hybrid	O
line	O
that	O
expresses	O
the	O
phenotypic	O
characteristics	O
of	O
primary	O
oligodendrocyte	O
[	O
19	O
,	O
20	O
].	O

MO3	O
.	O
13	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
’	O
s	O
Modified	O
Eagle	O
Medium	O
(	O
DMEM	O
)	O
(	O
Nacalai	O
Tesque	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
,	O
Gibco	O
),	O
penicillin	O
,	O
and	O
streptomycin	O
(	O
Gibco	O
)	O
in	O
a	O
humidified	O
5	O
%	O
CO2	O
incubator	O
at	O
37	O
°	O
C	O
.	O

MO3	O
.	O
13	O
cells	O
attain	O
a	O
flattened	O
bipolar	O
morphology	O
with	O
elongated	O
processes	O
and	O
can	O
be	O
differentiated	O
into	O
an	O
oligodendrocyte	O
phenotype	O
.	O

To	O
induce	O
differentiation	O
,	O
MO3	O
.	O
13	O
cells	O
were	O
cultured	O
in	O
DMEM	O
without	O
FBS	O
for	O
5	O
days	O
.	O

Serum	O
-	O
starved	O
differentiated	O
MO3	O
.	O
13	O
cells	O
were	O
exposed	O
to	O
CoCl2	O
(	O
500	O
μm	O
)	O
and	O
/	O
or	O
2ccPA	O
(	O
10	O
μm	O
)	O
for	O
2	O
days	O
.	O

MTT	O
(	O
5	O
mg	O
/	O
ml	O
)	O
was	O
added	O
to	O
each	O
well	O
,	O
followed	O
by	O
incubation	O
at	O
37	O
°	O
C	O
for	O
4	O
h	O
in	O
a	O
CO2	O
incubator	O
.	O

The	O
supernatants	O
were	O
carefully	O
removed	O
,	O
and	O
200	O
μl	O
of	O
isopropanol	O
was	O
added	O
to	O
each	O
well	O
.	O

The	O
optical	O
density	O
(	O
OD	O
)	O
of	O
the	O
solution	O
was	O
measured	O
at	O
570	O
nm	O
using	O
a	O
microplate	O
reader	O
(	O
BIO	O
-	O
RAD	O
).	O

Western	O
blotting	O
analysis	O

MO3	O
.	O
13	O
cells	O
were	O
harvested	O
with	O
ice	O
-	O
cold	O
PBS	O
,	O
homogenized	O
in	O
ice	O
-	O
cold	O
RIPA	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
150	O
mM	O
NaCl	O
,	O
5	O
mM	O
ethylenediaminetetraacetic	O
acid	O
(	O
EDTA	O
),	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
0	O
.	O
5	O
%	O
deoxycholate	O
)	O
containing	O
a	O
protease	B-GP
inhibitor	O
cocktail	O
(	O
Roche	O
)	O
and	O
left	O
at	O
4	O
°	O
C	O
for	O
30	O
min	O
.	O

The	O
homogenates	O
were	O
centrifuged	O
at	O
×	O
20	O
,	O
000g	O
at	O
4	O
°	O
C	O
for	O
15	O
min	O
,	O
and	O
the	O
resulting	O
supernatants	O
were	O
collected	O
as	O
whole	O
-	O
cell	O
lysates	O
,	O
from	O
which	O
protein	O
concentrations	O
were	O
determined	O
using	O
a	O
protein	O
assay	O
kit	O
(	O
Thermo	O
Scientific	O
).	O

Proteins	O
were	O
separated	O
on	O
conventional	O
12	O
%	O
acrylamide	O
SDS	O
gels	O
and	O
transferred	O
to	O
nitrocellulose	O
membranes	O
.	O

After	O
blocking	O
with	O
5	O
%	O
skim	O
milk	O
(	O
MEGMILK	O
SNOW	O
BRAND	O
Co	O
.	O

Ltd	O
.)	O
in	O
PBS	O
containing	O
0	O
.	O
05	O
%	O
Tween	O
20	O
(	O
PBS	O
-	O
T	O
),	O
the	O
membranes	O
were	O
incubated	O
with	O
the	O
appropriate	O
primary	O
antibodies	O
(	O
anti	O
-	O
GAPDH	B-GP
(	O
Millipore	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
Bax	B-GP
(	O
cell	O
signaling	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
Bcl	B-GP
-	I-GP
2	I-GP
(	O
cell	O
signaling	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
phospho	O
-	O
JNK	B-GP
(	O
p	O
-	O
JNK	B-GP
,	O
Cell	O
Signaling	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
phospho	O
-	O
p38MAPK	B-GP
(	O
p	O
-	O
p38MAPK	B-GP
,	O
cell	O
signaling	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
myelin	B-GP
basic	I-GP
protein	I-GP
(	O
MBP	B-GP
,	O
Santa	O
cruz	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
oligodendrocyte	B-GP
transcription	I-GP
factor	I-GP
1	I-GP
(	O
Olig1	B-GP
,	O
Rockland	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
glial	B-GP
fibrillary	I-GP
acidic	I-GP
protein	I-GP
(	O
GFAP	B-GP
,	O
Epitomics	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
glutamine	B-GP
synthetase	I-GP
(	O
GS	B-GP
,	O
Abcam	O
,	O
1	O
:	O
1000	O
))	O
overnight	O
,	O
followed	O
by	O
incubation	O
with	O
horseradish	B-OG
peroxidase	B-GP
-	O
conjugated	O
secondary	O
antibodies	O
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
with	O
PBS	O
-	O
T	O
three	O
times	O
,	O
the	O
membranes	O
were	O
treated	O
with	O
reagent	O
for	O
exposure	O
(	O
Chemi	O
-	O
Lumi	O
One	O
Super	O
,	O
Nacalai	O
Tesque	O
;	O
ImmunoStar	O
LD	O
,	O
Wako	O
).	O

Images	O
of	O
the	O
membranes	O
were	O
captured	O
using	O
a	O
C	O
-	O
DiGit	O
Blot	O
Scanner	O
(	O
LI	O
-	O
COR	O
)	O
and	O
subjected	O
to	O
ImageJ	O
1	O
.	O
46r	O
analysis	O
.	O

Animal	B-OG
procedures	O

Mice	B-OG
were	O
housed	O
in	O
appropriate	O
animal	B-OG
care	O
facilities	O
at	O
Saitama	O
Medical	O
University	O
(	O
Saitama	O
,	O
Japan	O
)	O
and	O
handled	O
in	O
accordance	O
with	O
established	O
international	O
guidelines	O
.	O

Experimental	O
protocols	O
were	O
approved	O
by	O
the	O
Animal	B-OG
Research	O
Committee	O
of	O
Saitama	O
Medical	O
University	O
.	O

C57BL	B-OG
/	I-OG
6J	I-OG
mice	I-OG
(	O
Tokyo	O
Laboratory	O
Animals	B-OG
Science	O
)	O
were	O
received	O
at	O
our	O
facility	O
at	O
10	O
weeks	O
of	O
age	O
.	O

Mice	B-OG
were	O
maintained	O
on	O
a	O
12	O
/	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
.	O

For	O
histology	O
,	O
mice	B-OG
were	O
intracardially	O
perfused	O
with	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
in	O
PBS	O
.	O

The	O
brain	O
and	O
lumbar	O
spinal	O
cord	O
tissues	O
were	O
removed	O
and	O
post	O
-	O
fixed	O
overnight	O
in	O
4	O
%	O
PFA	O
in	O
PBS	O
,	O
following	O
which	O
they	O
were	O
cryoprotected	O
in	O
30	O
%	O
sucrose	O
solution	O
in	O
PBS	O
,	O
snap	O
frozen	O
,	O
and	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
further	O
use	O
.	O

Coronal	O
brain	O
sections	O
(	O
25	O
μm	O
)	O
were	O
obtained	O
using	O
a	O
cryostat	O
(	O
CM1900	O
,	O
LEICA	O
)	O
and	O
mounted	O
on	O
gelatin	O
-	O
coated	O
glass	O
slides	O
[	O
21	O
].	O

Induction	O
of	O
cuprizone	O
model	O
and	O
2ccPA	O
treatment	O

Male	O
C57BL	B-OG
/	I-OG
6J	I-OG
mice	I-OG
were	O
given	O
ad	O
libitum	O
access	O
to	O
a	O
powdered	O
diet	O
(	O
CLEA	O
Japan	O
)	O
containing	O
0	O
.	O
2	O
%	O
bis	O
-	O
cyclohexanone	O
-	O
oxaldihydrazone	O
(	O
cuprizone	O
,	O
Merck	O
KGaA	O
).	O

Mice	B-OG
were	O
fed	O
the	O
cuprizone	O
diet	O
for	O
5	O
weeks	O
(	O
acute	O
peak	O
demyelination	B-DS
),	O
6	O
weeks	O
(	O
spontaneous	O
remyelination	O
),	O
and	O
10	O
weeks	O
(	O
chronic	O
demyelination	B-DS
).	O

In	O
the	O
present	O
study	O
,	O
2ccPA	O
was	O
chemically	O
synthesized	O
as	O
previously	O
described	O
(	O
Fig	O
.	O
2a	O
)	O
[	O
17	O
],	O
dissolved	O
in	O
saline	O
,	O
and	O
administered	O
at	O
a	O
dose	O
of	O
1	O
.	O
6	O
mg	O
/	O
kg	O
via	O
intraperitoneal	O
injection	O
once	O
daily	O
during	O
the	O
cuprizone	O
exposure	O
period	O
(	O
0	O
–	O
5	O
,	O
3	O
–	O
5	O
,	O
5	O
–	O
6	O
,	O
or	O
5	O
–	O
10	O
weeks	O
from	O
the	O
onset	O
of	O
exposure	O
).	O

The	O
protocol	O
for	O
2ccPA	O
administration	O
is	O
presented	O
in	O
Fig	O
.	O
1	O
.	O

Control	O
mice	B-OG
were	O
fed	O
a	O
cuprizone	O
-	O
free	O
diet	O
and	O
received	O
an	O
equal	O
dose	O
of	O
saline	O
via	O
intraperitoneal	O
injection	O
once	O
daily	O
during	O
each	O
experimental	O
period	O
.	O

Coronal	O
brain	O
sections	O
were	O
stained	O
for	O
myelin	O
using	O
Black	O
-	O
Gold	O
II	O
(	O
Histo	O
-	O
Chem	O
)	O
as	O
previously	O
described	O
[	O
22	O
].	O

Briefly	O
,	O
sections	O
were	O
incubated	O
in	O
a	O
0	O
.	O
3	O
%	O
Black	O
-	O
Gold	O
II	O
solution	O
for	O
12	O
min	O
,	O
rinsed	O
in	O
distilled	O
water	O
,	O
fixed	O
in	O
1	O
%	O
sodium	O
thiosulfate	O
,	O
rinsed	O
in	O
tap	O
water	O
,	O
and	O
air	O
-	O
dried	O
.	O

Sections	O
were	O
coverslipped	O
using	O
Poly	O
-	O
Mount	O
(	O
Polysciences	O
Inc	O
).	O

Black	O
-	O
Gold	O
II	O
(	O
Histo	O
-	O
Chem	O
)	O
stained	O
sections	O
were	O
selected	O
between	O
Bregma	O
−	O
0	O
.	O
22	O
and	O
−	O
0	O
.	O
58	O
mm	O
.	O

Sections	O
were	O
photographed	O
at	O
×	O
10	O
magnification	O
on	O
a	O
KEYENCE	O
BZ	O
-	O
X700	O
microscope	O
(	O
Keyence	O
Corporation	O
).	O

Images	O
were	O
captured	O
using	O
a	O
KEYENCE	O
BZ	O
-	O
X700	O
BZ	O
-	O
X	O
Analyzer	O
and	O
imported	O
into	O
ImageJ	O
1	O
.	O
46r	O
,	O
which	O
was	O
used	O
to	O
measure	O
the	O
mean	O
OD	O
within	O
the	O
middle	O
of	O
the	O
corpus	O
callosum	O
[	O
21	O
].	O

The	O
OD	O
of	O
the	O
tissue	O
-	O
free	O
area	O
was	O
used	O
as	O
a	O
background	O
,	O
and	O
blank	O
was	O
subtracted	O
from	O
the	O
ODs	O
for	O
tissue	O
.	O

The	O
resulting	O
ODs	O
for	O
myelin	O
in	O
each	O
mouse	B-OG
were	O
normalized	O
against	O
values	O
in	O
unchallenged	O
mice	B-OG
using	O
the	O
following	O
formula	O
:	O
myelin	O
score	O
(%)	O
=	O
(	O
density	O
reading	O
/	O
unchallenged	O
density	O
average	O
)	O
×	O
100	O
.	O
Fig	O
.	O
1Multiperiod	O
of	O
2ccPA	O
administration	O
protocol	O
.	O

For	O
protocol	O
A	O
,	O
2ccPA	O
was	O
administered	O
once	O
daily	O
via	O
intraperitoneal	O
injection	O
for	O
the	O
duration	O
of	O
the	O
5	O
-	O
week	O
period	O
of	O
cuprizone	O
exposure	O
(	O
0	O
–	O
5	O
weeks	O
:	O
acute	O
peak	O
demyelination	B-DS
).	O

For	O
protocol	O
B	O
,	O
2ccPA	O
was	O
administered	O
once	O
daily	O
via	O
intraperitoneal	O
injection	O
between	O
weeks	O
3	O
–	O
5	O
of	O
cuprizone	O
exposure	O
(	O
3	O
–	O
5	O
weeks	O
:	O
after	O
onset	O
of	O
demyelination	B-DS
).	O

For	O
protocol	O
C	O
,	O
2ccPA	O
was	O
administered	O
once	O
daily	O
via	O
intraperitoneal	O
injection	O
between	O
weeks	O
5	O
–	O
6	O
of	O
cuprizone	O
exposure	O
(	O
5	O
–	O
6	O
weeks	O
:	O
spontaneous	O
remyelination	O
).	O

For	O
protocol	O
D	O
,	O
2ccPA	O
was	O
administered	O
once	O
daily	O
via	O
intraperitoneal	O
injection	O
between	O
weeks	O
5	O
–	O
10	O
of	O
cuprizone	O
exposure	O
(	O
5	O
–	O
10	O
weeks	O
:	O
chronic	O
demyelination	B-DS
)	O

Electron	O
microscopy	O
analysis	O
of	O
myelin	O
sheath	O
thickness	O
and	O
axon	O
diameter	O
in	O
the	O
cuprizone	O
model	O

Mice	B-OG
were	O
anesthetized	O
and	O
perfused	O
with	O
PBS	O
as	O
described	O
in	O
the	O
preceding	O
sections	O
,	O
following	O
which	O
they	O
were	O
fixed	O
using	O
4	O
%	O
PFA	O
and	O
2	O
.	O
5	O
%	O
glutaraldehyde	O
in	O
phosphate	O
buffer	O
and	O
re	O
-	O
fixed	O
overnight	O
at	O
4	O
°	O
C	O
.	O

The	O
fixed	O
brains	O
were	O
sliced	O
into	O
1	O
–	O
2	O
-	O
mm	O
sections	O
.	O

Sections	O
containing	O
the	O
corpus	O
callosum	O
area	O
were	O
divided	O
into	O
segments	O
of	O
2	O
–	O
3	O
mm	O
and	O
washed	O
in	O
0	O
.	O
1	O
M	O
sodium	O
cacodylate	O
buffer	O
.	O

After	O
washing	O
,	O
the	O
tissue	O
was	O
post	O
-	O
fixed	O
with	O
1	O
%	O
osmium	O
tetroxide	O
.	O

Sections	O
were	O
dehydrated	O
in	O
an	O
ascending	O
alcohol	O
series	O
and	O
embedded	O
in	O
epoxy	O
resin	O
.	O

Ultrathin	O
sections	O
of	O
the	O
corpus	O
callosum	O
were	O
prepared	O
using	O
a	O
Reichert	O
-	O
Nissei	O
ULTRACUT	O
-	O
N	O
ultramicrotome	O
(	O
Nissei	O
Sangyo	O
).	O

Ultrathin	O
sections	O
were	O
stained	O
with	O
lead	O
nitrate	O
and	O
3	O
%	O
uranyl	O
acetate	O
in	O
water	O
.	O

Digital	O
images	O
were	O
acquired	O
using	O
a	O
JEM	O
-	O
1400	O
Transmission	O
Electron	O
Microscope	O
(	O
JEOL	O
Ltd	O
.).	O

Ultrathin	O
sections	O
(	O
70	O
nm	O
)	O
were	O
examined	O
with	O
a	O
transmission	O
electron	O
microscope	O
at	O
80	O
kV	O
[	O
23	O
].	O

The	O
number	O
of	O
myelinated	O
fibers	O
present	O
in	O
electron	O
microscope	O
pictures	O
was	O
counted	O
.	O

Using	O
ImageJ	O
1	O
.	O
46r	O
,	O
axonal	O
diameters	O
were	O
calculated	O
from	O
the	O
outer	O
perimeter	O
of	O
the	O
axon	O
divided	O
by	O
the	O
total	O
perimeter	O
of	O
the	O
axon	O
.	O

The	O
g	O
-	O
ratio	O
were	O
calculated	O
the	O
numerical	O
ratio	O
between	O
the	O
diameter	O
of	O
the	O
axon	O
proper	O
and	O
the	O
outer	O
diameter	O
of	O
the	O
myelinated	O
fibers	O
.	O

Pictures	O
were	O
randomly	O
chosen	O
for	O
each	O
mouse	B-OG
and	O
100	O
–	O
200	O
fibers	O
per	O
picture	O
were	O
calculated	O
.	O

The	O
data	O
are	O
shown	O
as	O
percent	O
of	O
myelinated	O
fibers	O
and	O
axonal	O
diameter	O
.	O

RNA	O
extraction	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O

Mice	B-OG
were	O
euthanized	O
,	O
and	O
tissue	O
from	O
the	O
corpus	O
callosum	O
was	O
collected	O
for	O
RNA	O
extraction	O
as	O
previously	O
reported	O
[	O
24	O
].	O

Briefly	O
,	O
gross	O
coronal	O
sections	O
were	O
obtained	O
between	O
approximately	O
Bregma	O
−	O
0	O
.	O
25	O
and	O
−	O
1	O
.	O
25	O
mm	O
.	O

Sagittal	O
cuts	O
were	O
made	O
through	O
the	O
cingulum	O
,	O
medial	O
to	O
each	O
lateral	O
ventricle	O
,	O
followed	O
by	O
cuts	O
above	O
and	O
below	O
the	O
corpus	O
callosum	O
to	O
remove	O
most	O
of	O
the	O
cortex	O
and	O
fornix	O
[	O
24	O
].	O

Corpus	O
callosum	O
tissue	O
samples	O
were	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
required	O
for	O
further	O
processing	O
.	O

Samples	O
of	O
fresh	O
frozen	O
corpus	O
callosum	O
were	O
processed	O
for	O
RNA	O
extraction	O
using	O
ISOGEN	O
(	O
Nippon	O
Gene	O
Co	O
.)	O
following	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Extracted	O
RNA	O
was	O
resuspended	O
in	O
RNase	B-GP
-	O
free	O
molecular	O
grade	O
water	O
(	O
Takara	O
Bio	O
Inc	O
.)	O
and	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
required	O
for	O
analysis	O
.	O

For	O
qPCR	O
,	O
total	O
RNA	O
(	O
3	O
μg	O
)	O
was	O
reverse	O
transcribed	O
using	O
a	O
PrimeScript	O
RT	O
reagent	O
kit	O
(	O
Takara	O
Bio	O
Inc	O
.).	O

qPCR	O
was	O
performed	O
using	O
the	O
7900	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
),	O
with	O
the	O
following	O
gene	O
-	O
specific	O
primers	O
:	O
phosphoglycerate	B-GP
kinase	I-GP
1	I-GP
(	O
PGK1	B-GP
,	O
forward	O
:	O
5	O
′-	O
ctgctgttccaagcatcaaa	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
gcatcttttcccttcccttc	O
-	O
3	O
′),	O
glial	B-GP
fibrillary	I-GP
acidic	I-GP
protein	I-GP
(	O
GFAP	B-GP
,	O
forward	O
:	O
5	O
′-	O
acgcttctccttgtctcgaa	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
cggcgatagtcgttagcttc	O
-	O
3	O
′),	O
ionized	B-GP
calcium	I-GP
binding	I-GP
adapter	I-GP
molecule	I-GP
1	I-GP
(	O
Iba1	B-GP
,	O
forward	O
:	O
5	O
′-	O
atgagccaaagcagggattt	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
gaccagttggcctcttgtgt	O
-	O
3	O
′),	O
NOD	B-GP
-	I-GP
like	I-GP
receptor	I-GP
family	I-GP
,	I-GP
pyrin	I-GP
domain	I-GP
containing	I-GP
3	I-GP
(	O
NLRP3	B-GP
,	O
forward	O
:	O
5	O
′-	O
ccttggaccaggttcagtgt	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
aggagatgtcgaagcagcat	O
-	O
3	O
′),	O
purinergic	B-GP
receptor	I-GP
P2X	I-GP
ligand	I-GP
-	I-GP
gated	I-GP
ion	I-GP
channel	I-GP
7	I-GP
(	O
P2X7R	B-GP
,	O
forward	O
:	O
5	O
′-	O
tgtgtgcattgacttgctca	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
cttgcagacttttcccaagc	O
-	O
3	O
′)	O
Interleukin	B-GP
-	I-GP
1	I-GP
beta	I-GP
(	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
forward	O
:	O
5	O
′-	O
gaccttccaggatgaggaca	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
aggccacaggtattttgtcg	O
-	O
3	O
′).	O

Q	O
-	O
PCR	O
conditions	O
were	O
95	O
°	O
C	O
for	O
30	O
s	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
5	O
s	O
at	O
95	O
°	O
C	O
and	O
34	O
s	O
at	O
60	O
°	O
C	O
.	O

The	O
level	O
of	O
target	O
gene	O
expression	O
was	O
calculated	O
using	O
the	O
ΔΔCT	O
method	O
[	O
25	O
].	O

Data	O
were	O
analyzed	O
using	O
the	O
relative	O
quantification	O
technique	O
.	O

qPCR	O
results	O
were	O
normalized	O
to	O
the	O
expression	O
levels	O
of	O
PGK1	B-GP
,	O
as	O
previously	O
reported	O
[	O
21	O
].	O

Relative	O
changes	O
in	O
gene	O
expression	O
are	O
reported	O
as	O
a	O
percentage	O
of	O
the	O
level	O
of	O
expression	O
in	O
control	O
mice	B-OG
.	O

Rotarod	O
test	O

We	O
used	O
an	O
accelerating	O
rotarod	O
treadmill	O
for	O
mice	B-OG
(	O
Mouse	B-OG
Rotarod	O
,	O
UgoBasile	O
)	O
to	O
evaluate	O
motor	O
balance	O
and	O
coordination	O
following	O
cuprizone	O
exposure	O
.	O

Mice	B-OG
exposed	O
to	O
cuprizone	O
for	O
5	O
weeks	O
(	O
2ccPA	O
administration	O
protocols	O
A	O
and	O
B	O
)	O
were	O
tested	O
on	O
the	O
rotarod	O
at	O
28	O
rpm	O
,	O
while	O
those	O
exposed	O
to	O
cuprizone	O
for	O
10	O
weeks	O
(	O
2ccPA	O
administration	O
protocol	O
D	O
)	O
were	O
tested	O
at	O
20	O
rpm	O
.	O

The	O
time	O
each	O
mouse	B-OG
stayed	O
on	O
the	O
rod	O
(	O
latency	O
time	O
)	O
was	O
recorded	O
by	O
a	O
trip	O
switch	O
under	O
the	O
floor	O
of	O
each	O
rotating	O
drum	O
,	O
with	O
a	O
maximum	O
recording	O
time	O
of	O
300	O
s	O
.	O

The	O
number	O
of	O
falls	O
(	O
from	O
the	O
cylinder	O
)	O
and	O
flips	O
(	O
when	O
the	O
animal	B-OG
clung	O
to	O
the	O
cylinder	O
)	O
were	O
also	O
counted	O
.	O

Induction	O
of	O
EAE	B-DS
and	O
2ccPA	O
treatment	O

Female	O
C57BL	B-OG
/	I-OG
6J	I-OG
mice	I-OG
were	O
immunized	O
with	O
MOG35	O
−	O
55	O
/	O
CFA	O
emulsion	O
pertussis	B-DS
toxin	O
kits	O
(	O
EK	O
-	O
2110	O
,	O
Hooke	O
laboratories	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
[	O
26	O
,	O
27	O
].	O

Briefly	O
,	O
0	O
.	O
1	O
ml	O
MOG35	O
−	O
55	O
/	O
CFA	O
emulsion	O
was	O
injected	O
subcutaneously	O
into	O
both	O
flanks	O
of	O
each	O
mouse	B-OG
(	O
0	O
.	O
2	O
ml	O
/	O
animal	B-OG
,	O
200	O
μg	O
of	O
MOG35	O
−	O
55	O
peptide	O
in	O
each	O
0	O
.	O
2	O
ml	O
dose	O
).	O

Mice	B-OG
then	O
received	O
intraperitoneal	O
injections	O
of	O
pertussis	B-DS
toxin	O
(	O
0	O
.	O
1	O
ml	O
/	O
animal	B-OG
/	O
day	O
,	O
400	O
ng	O
pertussis	B-DS
toxin	O
in	O
each	O
0	O
.	O
1	O
ml	O
dose	O
)	O
on	O
the	O
same	O
day	O
and	O
24	O
h	O
later	O
.	O

The	O
day	O
after	O
the	O
last	O
injection	O
of	O
MOG	B-GP
was	O
considered	O
day	O
1	O
.	O

Clinical	O
signs	O
were	O
scored	O
as	O
follows	O
:	O
0	O
,	O
no	O
clinical	O
sign	O
;	O
0	O
.	O
5	O
,	O
partial	O
tail	O
paralysis	O
;	O
1	O
.	O
0	O
,	O
complete	O
tail	O
paralysis	O
;	O
1	O
.	O
5	O
,	O
complete	O
tail	O
paralysis	O
and	O
discrete	O
hind	O
limb	O
weakness	O
;	O
2	O
.	O
0	O
,	O
complete	O
tail	O
paralysis	O
and	O
strong	O
hind	O
limb	O
weakness	O
;	O
2	O
.	O
5	O
,	O
unilateral	O
hind	O
limb	O
paralysis	O
;	O
3	O
,	O
complete	O
hind	O
limb	O
paralysis	O
;	O
3	O
.	O
5	O
,	O
hind	O
limb	O
paralysis	O
and	O
forelimb	O
weakness	O
;	O
4	O
.	O
0	O
,	O
complete	O
paralysis	O
(	O
tetraplegia	B-DS
),	O
and	O
5	O
.	O
0	O
,	O
moribund	O
or	O
dead	O
[	O
26	O
,	O
27	O
].	O

In	O
each	O
mouse	B-OG
,	O
2ccPA	O
was	O
administered	O
at	O
a	O
dose	O
of	O
16	O
mg	O
/	O
kg	O
via	O
intraperitoneal	O
injection	O
once	O
daily	O
for	O
the	O
duration	O
of	O
the	O
EAE	B-DS
protocol	O
(	O
days	O
0	O
–	O
30	O
or	O
17	O
–	O
30	O
).	O

Sections	O
were	O
stained	O
H	O
&	O
E	O
.	O

Five	O
random	O
sections	O
from	O
each	O
mouse	B-OG
were	O
observed	O
to	O
evaluate	O
the	O
degree	O
of	O
inflammation	O
[	O
28	O
].	O

For	O
evaluation	O
of	O
inflammation	O
,	O
a	O
four	O
-	O
point	O
scale	O
was	O
graded	O
as	O
follows	O
:	O
0	O
,	O
no	O
sign	O
or	O
minimal	O
inflammation	O
;	O
1	O
,	O
inflammatory	O
cell	O
infiltrates	O
in	O
meninges	O
;	O
2	O
,	O
perivascular	O
inflammatory	O
cell	O
infiltrates	O
;	O
and	O
3	O
,	O
marked	O
infiltration	O
of	O
inflammatory	O
cells	O
into	O
the	O
parenchyma	O
.	O

The	O
histological	O
score	O
represented	O
the	O
mean	O
of	O
the	O
scores	O
of	O
all	O
sections	O
examined	O
[	O
28	O
].	O

Immunohistochemistry	O

Brain	O
sections	O
were	O
incubated	O
with	O
rabbit	B-OG
anti	O
-	O
Iba1	B-GP
antibody	O
(	O
Wako	O
,	O
1	O
:	O
250	O
),	O
rabbit	B-OG
anti	O
-	O
CD4	B-GP
antibody	O
(	O
Bioss	O
,	O
1	O
:	O
250	O
),	O
and	O
rat	B-OG
anti	O
-	O
F4	O
/	O
80	O
antibody	O
(	O
Bio	O
-	O
Rad	O
,	O
1	O
:	O
250	O
)	O
at	O
4	O
°	O
C	O
overnight	O
,	O
followed	O
by	O
incubation	O
at	O
room	O
temperature	O
for	O
1	O
h	O
with	O
the	O
secondary	O
antibody	O
(	O
Cy3	O
-	O
conjugated	O
AffiniPure	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
IgG	O
,	O
Jackson	O
ImmunoReseach	O
,	O
1	O
:	O
500	O
).	O

Sections	O
were	O
acquired	O
using	O
a	O
KEYENCE	O
BZ	O
-	O
X700	O
microscope	O
(	O
Keyence	O
Corporation	O
).	O

The	O
images	O
were	O
acquired	O
sequentially	O
using	O
the	O
561	O
nm	O
wavelength	O
of	O
a	O
light	O
-	O
emitting	O
diode	O
(	O
LED	O
)	O
to	O
Cy3	O
.	O

All	O
images	O
were	O
acquired	O
using	O
a	O
UPLSAPO	O
×	O
40	O
numerical	O
aperture	O
0	O
.	O
95	O
dry	O
objective	O
lens	O
(	O
Olympus	O
).	O

The	O
fluorescence	O
intensity	O
was	O
measured	O
by	O
ImageJ	O
1	O
.	O
46r	O
.	O

Statistical	O
analysis	O

The	O
number	O
of	O
falls	O
and	O
flips	O
was	O
analyzed	O
using	O
a	O
nonparametric	O
Kruskal	O
-	O
Wallis	O
test	O
.	O

EAE	B-DS
score	O
was	O
analyzed	O
using	O
a	O
nonparametric	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

The	O
protein	O
levels	O
of	O
oligodendrocyte	O
and	O
astrocyte	O
markers	O
were	O
analyzed	O
using	O
a	O
student	O
’	O
s	O
t	O
test	O
.	O

All	O
other	O
data	O
were	O
analyzed	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
Newman	O
-	O
Keuls	O
post	O
hoc	O
test	O
.	O

All	O
data	O
were	O
analyzed	O
using	O
GraphPad	O
Prism	O
Ver	O
.	O

5	O
.	O
01	O
(	O
Graphpad	O
Software	O
Inc	O
.)	O
and	O
expressed	O
as	O
the	O
mean	O
±	O
SEM	O
.	O
P	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

Results	O

2ccPA	O
protected	O
oligodendrocyte	O
cells	O
from	O
mitochondrial	O
apoptosis	O

We	O
undertook	O
in	O
vitro	O
investigations	O
using	O
the	O
MO3	O
.	O
13	O
oligodendrocyte	O
cell	O
line	O
,	O
an	O
immortalized	O
human	B-OG
-	O
human	B-OG
hybrid	O
cell	O
line	O
that	O
can	O
undergo	O
differentiation	O
into	O
an	O
oligodendrocyte	O
phenotype	O
.	O

In	O
the	O
present	O
study	O
,	O
undifferentiated	O
MO3	O
.	O
13	O
cells	O
with	O
few	O
processes	O
(	O
Fig	O
.	O
2b	O
)	O
were	O
cultured	O
in	O
DMEM	O
without	O
FBS	O
for	O
5	O
days	O
to	O
induce	O
differentiation	O
.	O

Serum	O
-	O
starved	O
differentiated	O
MO3	O
.	O
13	O
cells	O
exhibited	O
increases	O
in	O
process	O
length	O
(	O
Fig	O
.	O
2c	O
).	O

Differentiated	O
cells	O
exhibited	O
expression	O
of	O
the	O
oligodendrocyte	O
markers	O
MBP	B-GP
and	O
Olig1	B-GP
(	O
Fig	O
.	O
2d	O
–	O
f	O
)	O
and	O
decreased	O
expression	O
of	O
the	O
astrocyte	O
marker	O
GS	B-GP
(	O
Fig	O
.	O
2d	O
,	O
g	O
).	O

No	O
GFAP	B-GP
(	O
another	O
astrocytic	O
marker	O
)	O
expression	O
was	O
detected	O
in	O
either	O
phenotype	O
(	O
Fig	O
.	O
2d	O
).	O

Differentiated	O
MO3	O
.	O
13	O
cells	O
were	O
then	O
used	O
for	O
subsequent	O
experiments	O
.	O

To	O
induce	O
mitochondrial	O
apoptosis	O
in	O
vitro	O
,	O
CoCl2	O
(	O
cobalt	O
chloride	O
),	O
a	O
chemical	O
mitochondrial	O
apoptosis	O
-	O
inducing	O
agent	O
,	O
was	O
added	O
in	O
the	O
presence	O
or	O
absence	O
of	O
2ccPA	O
,	O
and	O
cell	O
viability	O
was	O
evaluated	O
using	O
MTT	O
.	O

Treatment	O
with	O
2ccPA	O
significantly	O
increased	O
cell	O
viability	O
in	O
the	O
presence	O
of	O
CoCl2	O
(	O
Fig	O
.	O
2h	O
).	O

The	O
Bcl	B-GP
-	I-GP
2	I-GP
family	O
is	O
an	O
important	O
regulator	O
of	O
mitochondrial	O
dysfunction	O
,	O
which	O
is	O
induced	O
via	O
apoptosis	O
pathways	O
.	O

Mitochondrial	O
dysfunction	O
induces	O
an	O
increase	O
in	O
the	O
expression	O
of	O
proapoptotic	O
proteins	O
,	O
such	O
as	O
Bax	B-GP
,	O
and	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
antiapoptotic	O
proteins	O
,	O
such	O
as	O
Bcl	B-GP
-	I-GP
2	I-GP
.	O

Bax	B-GP
and	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	O
levels	O
were	O
determined	O
by	O
Western	O
blot	O
analysis	O
(	O
Fig	O
.	O
2i	O
),	O
and	O
the	O
Bax	B-GP
/	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	O
expression	O
ratio	O
was	O
evaluated	O
(	O
Fig	O
.	O
2j	O
).	O

The	O
Bax	B-GP
/	O
Bcl	B-GP
-	I-GP
2	I-GP
ratio	O
increased	O
with	O
CoCl2	O
exposure	O
.	O

Treatment	O
with	O
2ccPA	O
suppressed	O
the	O
CoCl2	O
-	O
induced	O
increase	O
in	O
the	O
Bax	B-GP
/	O
Bcl	B-GP
-	I-GP
2	I-GP
ratio	O
,	O
which	O
suggested	O
that	O
2ccPA	O
protected	O
oligodendrocyte	O
cells	O
from	O
CoCl2	O
-	O
induced	O
mitochondrial	O
apoptosis	O
.	O

In	O
addition	O
,	O
we	O
observed	O
activation	O
of	O
p38MAPK	B-GP
and	O
JNK	B-GP
during	O
CoCl2	O
-	O
induced	O
apoptosis	O
[	O
29	O
,	O
30	O
].	O

CoCl2	O
increased	O
the	O
phosphorylation	O
levels	O
of	O
p38MAPK	B-GP
and	O
JNK	B-GP
protein	O
,	O
which	O
were	O
suppressed	O
by	O
2ccPA	O
treatment	O
(	O
Fig	O
.	O
2k	O
,	O
l	O
).	O

These	O
data	O
indicate	O
that	O
2ccPA	O
suppressed	O
the	O
CoCl2	O
-	O
induced	O
apoptosis	O
by	O
inhibiting	O
the	O
phosphorylation	O
of	O
p38MAPK	B-GP
and	O
JNK	B-GP
.	O
Fig	O
.	O
2Structure	O
and	O
effect	O
of	O
2ccPA	O
on	O
CoCl2	O
-	O
induced	O
apoptosis	O
.	O

Structure	O
of	O
2ccPA	O
18	O
:	O
1	O
.	O

2ccPA	O
is	O
the	O
compound	O
in	O
which	O
one	O
of	O
the	O
phosphate	O
oxygen	O
is	O
replaced	O
with	O
a	O
methylene	O
group	O
at	O
the	O
sn	O
-	O
2	O
position	O
(	O
a	O
).	O

Chemically	O
synthesized	O
cPA	O
derivative	O
,	O
2ccPA	O
,	O
used	O
for	O
the	O
present	O
experiments	O
.	O

Light	O
microscopic	O
undifferentiated	O
MO3	O
.	O
13	O
cells	O
(	O
b	O
)	O
and	O
differentiated	O
MO3	O
.	O
13	O
cells	O
(	O
c	O
).	O
Scale	O
bar	O
=	O
100	O
μm	O
.	O

The	O
protein	O
levels	O
of	O
MBP	B-GP
,	O
Olig1	B-GP
,	O
GFAP	B-GP
,	O
GS	B-GP
,	O
and	O
GAPDH	B-GP
determined	O
by	O
Western	O
blot	O
analysis	O
(	O
d	O
).	O

Protein	O
levels	O
of	O
MBP	B-GP
(	O
e	O
),	O
Olig1	B-GP
(	O
f	O
),	O
and	O
GS	B-GP
(	O
g	O
).	O

Data	O
are	O
presented	O
as	O
the	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
6	O
.	O

Statistical	O
analysis	O
were	O
performed	O
using	O
a	O
student	O
’	O
s	O
t	O
test	O
.	O

(*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
vs	O
.	O
control	O
).	O

MO3	O
.	O
13	O
cells	O
were	O
incubated	O
with	O
500	O
μm	O
CoCl2	O
in	O
the	O
presence	O
of	O
10	O
μm	O
2ccPA	O
.	O

Cell	O
viability	O
of	O
MO3	O
.	O
13	O
cells	O
were	O
evaluated	O
using	O
MTT	O
assay	O
(	O
h	O
).	O

The	O
protein	O
levels	O
of	O
Bax	B-GP
,	O
Bcl	B-GP
-	I-GP
2	I-GP
,	O
phosphorylated	O
-	O
p38MAPK	B-GP
(	O
p	O
-	O
p38MAPK	B-GP
),	O
phosphorylated	O
-	O
JNK	B-GP
(	O
p	O
-	O
JNK	B-GP
),	O
and	O
GAPDH	B-GP
were	O
determined	O
by	O
Western	O
blot	O
analysis	O
(	O
i	O
).	O

The	O
expression	O
of	O
Bax	B-GP
and	O
Bcl	B-GP
-	I-GP
2	I-GP
was	O
determined	O
using	O
a	O
densitometer	O
,	O
and	O
the	O
Bax	B-GP
/	O
Bcl	B-GP
-	I-GP
2	I-GP
ratio	O
was	O
calculated	O
(	O
j	O
).	O

Protein	O
levels	O
of	O
p	O
-	O
p38MAPK	B-GP
(	O
k	O
)	O
and	O
p	O
-	O
JNK	B-GP
(	O
l	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
6	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CoCl2	O
)	O

2ccPA	O
suppressed	O
the	O
cuprizone	O
-	O
induced	O
acute	O
peak	O
demyelination	B-DS

To	O
investigate	O
the	O
effects	O
of	O
2ccPA	O
on	O
cuprizone	O
-	O
induced	O
acute	O
peak	O
demyelination	B-DS
,	O
we	O
fed	O
mice	B-OG
a	O
cuprizone	O
diet	O
and	O
administrated	O
2ccPA	O
for	O
5	O
weeks	O
(	O
Fig	O
.	O
1	O
,	O
protocol	O
A	O
).	O

Myelin	O
content	O
was	O
quantified	O
using	O
Black	O
-	O
Gold	O
II	O
staining	O
.	O

In	O
control	O
mice	B-OG
,	O
the	O
corpus	O
callosum	O
appeared	O
to	O
retain	O
sufficient	O
myelin	O
content	O
(	O
Fig	O
.	O
3a	O
).	O

Five	O
weeks	O
of	O
cuprizone	O
exposure	O
induced	O
acute	O
peak	O
demyelination	B-DS
in	O
the	O
corpus	O
callosum	O
(	O
Fig	O
.	O
3b	O
).	O

2ccPA	O
treatment	O
suppressed	O
the	O
acute	O
peak	O
demyelination	B-DS
almost	O
completely	O
(	O
Fig	O
.	O
3c	O
,	O
d	O
).	O

Electron	O
microscopy	O
was	O
then	O
used	O
to	O
obtain	O
data	O
for	O
quantitative	O
analysis	O
of	O
myelinated	O
axons	O
,	O
axonal	O
diameter	O
,	O
and	O
g	O
-	O
ratios	O
.	O

Control	O
mice	B-OG
exhibited	O
full	O
myelination	O
in	O
the	O
corpus	O
callosum	O
(	O
Fig	O
.	O
3e	O
).	O

In	O
contrast	O
,	O
mice	B-OG
exposed	O
to	O
cuprizone	O
for	O
5	O
weeks	O
exhibited	O
a	O
decrease	O
in	O
the	O
extent	O
of	O
myelination	O
and	O
residual	O
myelin	O
sheaths	O
(	O
Fig	O
.	O
3f	O
),	O
while	O
treatment	O
with	O
2ccPA	O
attenuated	O
this	O
decrease	O
in	O
myelination	O
(	O
Fig	O
.	O
3g	O
).	O

In	O
addition	O
,	O
2ccPA	O
treatment	O
significantly	O
increased	O
the	O
number	O
of	O
myelinated	O
axons	O
(	O
Fig	O
.	O
3h	O
),	O
reduced	O
axonal	O
diameter	O
(	O
Fig	O
.	O
3i	O
),	O
and	O
lowered	O
g	O
-	O
ratios	O
(	O
Fig	O
.	O
3j	O
)	O
in	O
comparison	O
to	O
values	O
obtained	O
for	O
cuprizone	O
-	O
treated	O
mice	B-OG
.	O

These	O
findings	O
indicate	O
that	O
treatment	O
with	O
2ccPA	O
suppresses	O
cuprizone	O
-	O
induced	O
axonal	O
damage	O
and	O
demyelination	B-DS
.	O
Fig	O
.	O
32ccPA	O
suppressed	O
the	O
cuprizone	O
-	O
induced	O
acute	O
peak	O
demyelination	B-DS
.	O

Representative	O
photomicrographs	O
of	O
coronal	O
brain	O
sections	O
at	O
the	O
level	O
of	O
the	O
fimbria	O
demonstrate	O
progressive	O
demyelination	B-DS
of	O
the	O
corpus	O
callosum	O
after	O
5	O
weeks	O
of	O
cuprizone	O
(	O
CPZ	O
)	O
exposure	O
.	O

Black	O
-	O
Gold	O
II	O
staining	O
in	O
the	O
control	O
(	O
a	O
),	O
CPZ	O
+	O
Ssaline	O
(	O
b	O
),	O
and	O
CPZ	O
+	O
2ccPA	O
(	O
c	O
)	O
groups	O
.	O

Myelin	O
densities	O
in	O
the	O
corpus	O
callosum	O
(	O
d	O
)	O
were	O
compared	O
with	O
those	O
of	O
controls	O
and	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
control	O
value	O
using	O
the	O
ImageJ	O
analysis	O
program	O
.	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
5	O
animals	B-OG
.	O
Scale	O
bars	O
=	O
500	O
mm	O
.	O

Electron	O
micrographs	O
demonstrate	O
an	O
acute	O
peak	O
demyelination	B-DS
of	O
the	O
corpus	O
callosum	O
after	O
5	O
weeks	O
of	O
CPZ	O
exposure	O
.	O

Electron	O
micrographs	O
of	O
control	O
(	O
e	O
),	O
CPZ	O
+	O
Saline	O
(	O
f	O
),	O
and	O
CPZ	O
+	O
2ccPA	O
(	O
g	O
)	O
in	O
the	O
corpus	O
callosum	O
.	O

Myelinated	O
axons	O
(	O
h	O
),	O
axonal	O
diameter	O
(	O
i	O
),	O
and	O
g	O
-	O
ratio	O
(	O
j	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
7	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CPZ	O
+	O
Saline	O
).	O
Scale	O
bar	O
=	O
5	O
μm	O

2ccPA	O
suppressed	O
the	O
neuroinflammation	O

We	O
evaluated	O
glial	O
activation	O
and	O
inflammasome	O
formation	O
to	O
investigate	O
the	O
effect	O
of	O
2ccPA	O
on	O
the	O
neuroinflammation	O
associated	O
with	O
demyelination	B-DS
.	O

Levels	O
of	O
gene	O
expression	O
for	O
the	O
microglial	O
marker	O
(	O
Iba1	B-GP
)	O
and	O
astrocytic	O
marker	O
(	O
GFAP	B-GP
)	O
were	O
evaluated	O
after	O
5	O
weeks	O
of	O
cuprizone	O
.	O

Cuprizone	O
exposure	O
increased	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
levels	O
of	O
Iba1	B-GP
and	O
GFAP	B-GP
.	O

2ccPA	O
treatment	O
suppressed	O
cuprizone	O
-	O
induced	O
increases	O
in	O
Iba1	B-GP
and	O
GFAP	B-GP
mRNA	O
expression	O
(	O
Fig	O
.	O
4a	O
,	O
b	O
).	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
NLRP3	B-GP
inflammasome	O
plays	O
an	O
essential	O
role	O
in	O
neuroinflammatory	O
diseases	O
including	O
multiple	B-DS
sclerosis	I-DS
[	O
9	O
].	O

We	O
analyzed	O
the	O
gene	O
expression	O
levels	O
of	O
NLRP3	B-GP
inflammasome	O
-	O
related	O
genes	O
such	O
as	O
NLRP3	B-GP
,	O
P2X7R	B-GP
,	O
and	O
IL	B-GP
-	I-GP
1β	I-GP
.	O

NLRP3	B-GP
,	O
P2X7R	B-GP
,	O
and	O
IL	B-GP
-	I-GP
1β	I-GP
expression	O
levels	O
were	O
increased	O
by	O
cuprizone	O
exposure	O
and	O
were	O
suppressed	O
by	O
2ccPA	O
treatment	O
(	O
Fig	O
.	O
4c	O
–	O
e	O
).	O

Iba1	B-GP
-	O
positive	O
microglia	O
were	O
detected	O
by	O
immunofluorescence	O
analysis	O
in	O
the	O
corpus	O
callosum	O
(	O
Fig	O
.	O
4f	O
–	O
k	O
).	O

Microglia	O
were	O
seen	O
only	O
sporadically	O
in	O
the	O
corpus	O
callosum	O
of	O
the	O
control	O
mice	B-OG
(	O
Fig	O
.	O
4f	O
,	O
g	O
).	O

Mice	B-OG
exposed	O
to	O
cuprizone	O
exhibited	O
hypertrophic	O
microglia	O
with	O
enlarged	O
cell	O
bodies	O
(	O
Fig	O
.	O
4h	O
,	O
i	O
),	O
which	O
were	O
suppressed	O
by	O
2ccPA	O
treatment	O
(	O
Fig	O
.	O
4j	O
,	O
k	O
).	O

The	O
cuprizone	O
-	O
induced	O
increases	O
in	O
microglia	O
in	O
the	O
corpus	O
callosum	O
were	O
reduced	O
by	O
2ccPA	O
treatment	O
(	O
Fig	O
.	O
4l	O
).	O

We	O
observed	O
no	O
significant	O
difference	O
in	O
levels	O
of	O
gene	O
expression	O
for	O
the	O
alternative	O
markers	O
of	O
microglial	O
activation	O
Arg1	B-GP
,	O
Fizz1	B-GP
,	O
and	O
Ym1	B-GP
among	O
corpus	O
callosum	O
tissue	O
samples	O
(	O
Control	O
,	O
CPZ	O
+	O
saline	O
,	O
CPZ	O
+	O
2ccPA	O
)	O
(	O
data	O
not	O
shown	O
).	O

These	O
findings	O
indicate	O
that	O
treatment	O
with	O
2ccPA	O
effectively	O
suppressed	O
cuprizone	O
-	O
induced	O
NLRP3	B-GP
inflammasome	O
formation	O
and	O
microglial	O
activation	O
.	O
Fig	O
.	O
42ccPA	O
suppressed	O
the	O
neuroinflammation	O
.	O

The	O
mRNA	O
levels	O
of	O
Iba1	B-GP
(	O
a	O
),	O
GFAP	B-GP
(	O
b	O
),	O
NLRP3	B-GP
(	O
c	O
),	O
P2X7R	B-GP
(	O
d	O
),	O
and	O
IL	B-GP
-	I-GP
1β	I-GP
(	O
e	O
)	O
relative	O
to	O
PGK1	B-GP
,	O
as	O
determined	O
by	O
qPCR	O
in	O
the	O
corpus	O
callosum	O
after	O
5	O
weeks	O
of	O
CPZ	O
exposure	O
.	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
5	O
animals	B-OG
.	O

Immunostaining	O
with	O
anti	O
-	O
Iba1	B-GP
showed	O
microglial	O
activation	O
in	O
the	O
corpus	O
callosum	O
.	O

Control	O
(	O
f	O
,	O
g	O
),	O
CPZ	O
+	O
saline	O
(	O
h	O
,	O
i	O
),	O
and	O
CPZ	O
+	O
2ccPA	O
(	O
j	O
,	O
k	O
).	O

Number	O
of	O
microglia	O
in	O
the	O
corpus	O
callosum	O
(	O
l	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
6	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
#	O
p	O
<	O
0	O
.	O
01	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CPZ	O
+	O
saline	O
).	O
Scale	O
bar	O
500	O
-	O
μm	O
left	O
images	O
;	O
50	O
-	O
μm	O
right	O
images	O

Beneficial	O
effects	O
of	O
2ccPA	O
in	O
the	O
multiperiod	O
of	O
cuprizone	O
-	O
induced	O
demyelination	B-DS

We	O
investigated	O
the	O
therapeutic	O
potential	O
of	O
2ccPA	O
in	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
.	O

In	O
three	O
experimental	O
settings	O
,	O
2ccPA	O
treatment	O
was	O
administrated	O
during	O
at	O
weeks	O
3	O
–	O
5	O
(	O
protocol	O
B	O
:	O
beginning	O
of	O
substantial	O
demyelination	B-DS
and	O
motor	O
dysfunction	O
),	O
weeks	O
5	O
–	O
6	O
(	O
protocol	O
C	O
:	O
spontaneous	O
remyelination	O
),	O
or	O
weeks	O
5	O
–	O
10	O
(	O
protocol	O
D	O
:	O
chronic	O
severe	O
demyelination	B-DS
)	O
of	O
cuprizone	O
exposure	O
.	O

Treatment	O
with	O
2ccPA	O
(	O
protocol	O
B	O
)	O
suppressed	O
acute	O
peak	O
demyelination	B-DS
after	O
the	O
onset	O
of	O
cuprizone	O
-	O
induced	O
neurological	O
symptoms	O
(	O
Fig	O
.	O
5a	O
–	O
d	O
).	O

It	O
is	O
well	O
known	O
that	O
spontaneous	O
remyelination	O
occurs	O
following	O
acute	O
demyelination	B-DS
in	O
the	O
corpus	O
callosum	O
of	O
cuprizone	O
model	O
mice	B-OG
.	O

At	O
6	O
weeks	O
of	O
cuprizone	O
exposure	O
,	O
we	O
observed	O
spontaneous	O
remyelination	O
in	O
cuprizone	O
mice	B-OG
(	O
Fig	O
.	O
5f	O
).	O

Treatment	O
with	O
2ccPA	O
during	O
the	O
final	O
week	O
(	O
protocol	O
C	O
)	O
significantly	O
promoted	O
spontaneous	O
remyelination	O
(	O
Fig	O
.	O
5e	O
–	O
h	O
).	O

Prolonged	O
cuprizone	O
exposure	O
resulted	O
in	O
chronic	O
demyelination	B-DS
.	O

Treatment	O
with	O
2ccPA	O
(	O
5	O
–	O
10	O
weeks	O
)	O
reduced	O
chronic	O
demyelination	B-DS
(	O
Fig	O
.	O
5i	O
–	O
l	O
).	O

These	O
results	O
demonstrate	O
that	O
2ccPA	O
exerts	O
beneficial	O
effects	O
in	O
the	O
multiperiod	O
of	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
.	O
Fig	O
.	O
5Effects	O
of	O
2ccPA	O
in	O
the	O
multiperiod	O
of	O
CPZ	O
-	O
induced	O
demyelination	B-DS
and	O
motor	O
dysfunction	O
.	O

Black	O
-	O
Gold	O
II	O
staining	O
of	O
control	O
(	O
a	O
,	O
e	O
,	O
and	O
i	O
),	O
CPZ	O
+	O
saline	O
(	O
b	O
,	O
f	O
,	O
and	O
j	O
),	O
CPZ	O
+	O
2ccPA	O
(	O
c	O
,	O
g	O
,	O
and	O
k	O
).	O

Myelin	O
densities	O
in	O
the	O
corpus	O
callosum	O
(	O
d	O
,	O
h	O
,	O
and	O
l	O
)	O
were	O
compared	O
with	O
controls	O
and	O
expressed	O
as	O
a	O
percentage	O
of	O
control	O
value	O
using	O
the	O
ImageJ	O
analysis	O
program	O
.	O

Data	O
are	O
mean	O
±	O
SEM	O
.,	O
n	O
=	O
5	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
##	O
p	O
<	O
0	O
.	O
01	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CPZ	O
+	O
saline	O
).	O
Scale	O
bars	O
=	O
500	O
μm	O
.	O

Motor	O
performance	O
on	O
the	O
rotarod	O
.	O

Mice	B-OG
were	O
assessed	O
for	O
locomotion	O
time	O
during	O
a	O
period	O
of	O
300	O
s	O
(	O
m	O
,	O
o	O
,	O
and	O
q	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
.,	O
n	O
=	O
12	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CPZ	O
+	O
saline	O
).	O

Number	O
of	O
falls	O
and	O
flips	O
(	O
n	O
,	O
p	O
,	O
and	O
r	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
.,	O
n	O
=	O
12	O
animals	B-OG
(	O
0	O
–	O
5	O
weeks	O
group	O
),	O
n	O
=	O
10	O
animals	B-OG
(	O
3	O
–	O
5	O
weeks	O
group	O
),	O
and	O
n	O
=	O
15	O
animals	B-OG
(	O
5	O
–	O
10	O
weeks	O
group	O
).	O

Statistical	O
analysis	O
was	O
performed	O
using	O
non	O
-	O
parametric	O
Kruskal	O
-	O
Wallis	O
test	O
(*	O
p	O
<	O
0	O
.	O
05	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
#	O
p	O
<	O
0	O
.	O
05	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CPZ	O
+	O
saline	O
)	O

2ccPA	O
improved	O
cuprizone	O
-	O
induced	O
motor	O
dysfunction	O

To	O
investigate	O
the	O
effects	O
of	O
2ccPA	O
on	O
motor	O
dysfunction	O
caused	O
by	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
,	O
we	O
assessed	O
the	O
locomotor	O
coordination	O
and	O
balance	O
of	O
mice	B-OG
using	O
a	O
rotarod	O
apparatus	O
.	O

Mice	B-OG
exposed	O
to	O
cuprizone	O
(	O
0	O
–	O
5	O
and	O
5	O
–	O
10	O
weeks	O
)	O
exhibited	O
significant	O
decreases	O
in	O
locomotion	O
time	O
as	O
well	O
as	O
significant	O
increases	O
in	O
the	O
number	O
of	O
falls	O
and	O
flips	O
.	O

Treatment	O
with	O
2ccPA	O
(	O
protocols	O
A	O
,	O
B	O
,	O
and	O
D	O
)	O
significantly	O
restored	O
locomotion	O
time	O
remarkably	O
(	O
Fig	O
.	O
5m	O
,	O
o	O
,	O
and	O
q	O
)	O
and	O
suppressed	O
the	O
number	O
of	O
falls	O
and	O
flips	O
(	O
Fig	O
.	O
5n	O
,	O
p	O
,	O
and	O
r	O
).	O

2ccPA	O
treatment	O
significantly	O
suppressed	O
the	O
cuprizone	O
-	O
induced	O
impairment	O
of	O
motor	O
performance	O
.	O

2ccPA	O
ameliorated	O
EAE	B-DS
pathology	O

We	O
assessed	O
the	O
potential	O
of	O
2ccPA	O
to	O
improve	O
the	O
disease	O
course	O
in	O
the	O
EAE	B-DS
model	O
mice	B-OG
.	O

Mice	B-OG
were	O
monitored	O
daily	O
for	O
clinical	O
symptoms	O
and	O
scored	O
in	O
accordance	O
with	O
established	O
criteria	O
[	O
31	O
].	O

Control	O
mice	B-OG
exhibited	O
no	O
obvious	O
symptoms	O
of	O
EAE	B-DS
disease	O
.	O

In	O
contrast	O
,	O
EAE	B-DS
mice	B-OG
developed	O
severe	O
EAE	B-DS
symptoms	O
,	O
although	O
treatment	O
with	O
2ccPA	O
significantly	O
reduced	O
clinical	O
EAE	B-DS
scores	O
.	O

Indeed	O
,	O
a	O
large	O
difference	O
in	O
disease	O
severity	O
between	O
the	O
control	O
and	O
treatment	O
groups	O
was	O
observed	O
throughout	O
the	O
observation	O
period	O
(	O
Fig	O
.	O
6a	O
).	O

Mean	O
clinical	O
EAE	B-DS
scores	O
were	O
significantly	O
lower	O
for	O
2ccPA	O
-	O
treated	O
mice	B-OG
than	O
EAE	B-DS
mice	B-OG
.	O

Although	O
EAE	B-DS
mice	B-OG
peaked	O
at	O
scores	O
of	O
3	O
–	O
4	O
following	O
immunization	O
,	O
2ccPA	O
-	O
treated	O
mice	B-OG
peaked	O
at	O
scores	O
of	O
1	O
following	O
immunization	O
.	O

We	O
then	O
examined	O
the	O
therapeutic	O
potential	O
of	O
2ccPA	O
in	O
mice	B-OG
already	O
exhibiting	O
EAE	B-DS
symptoms	O
.	O

2ccPA	O
successfully	O
attenuated	O
clinical	O
EAE	B-DS
symptoms	O
even	O
after	O
the	O
peak	O
stages	O
of	O
disease	O
(	O
Fig	O
.	O
6b	O
),	O
suggesting	O
that	O
treatment	O
with	O
2ccPA	O
dramatically	O
suppresses	O
impairments	O
in	O
neurological	O
function	O
.	O

Inflammatory	O
infiltration	O
of	O
immune	O
cells	O
in	O
the	O
spinal	O
cord	O
is	O
a	O
well	O
-	O
documented	O
histological	O
feature	O
of	O
the	O
EAE	B-DS
model	O
.	O

Inflammatory	O
infiltration	O
of	O
immune	O
cells	O
in	O
the	O
spinal	O
cords	O
was	O
a	O
histological	O
feature	O
of	O
the	O
EAE	B-DS
model	O
.	O

The	O
spinal	O
cords	O
were	O
stained	O
with	O
H	O
&	O
E	O
to	O
assess	O
the	O
degree	O
of	O
inflammation	O
.	O

Inflammatory	O
cells	O
penetrated	O
the	O
pia	O
mater	O
and	O
infiltrated	O
the	O
perivascular	O
regions	O
and	O
parenchyma	O
.	O

Control	O
myelin	O
of	O
the	O
white	O
matter	O
was	O
highlighted	O
clearly	O
by	O
H	O
&	O
E	O
staining	O
(	O
Fig	O
.	O
6c	O
).	O

In	O
EAE	B-DS
mice	B-OG
,	O
we	O
found	O
mononuclear	O
infiltration	O
in	O
the	O
leptomeninges	O
and	O
scattered	O
throughout	O
the	O
white	O
matter	O
parenchyma	O
(	O
Fig	O
.	O
6d	O
).	O

We	O
observed	O
severe	O
inflammation	O
with	O
vacuolation	O
in	O
the	O
anterior	O
and	O
lateral	O
funiculi	O
of	O
the	O
spinal	O
cord	O
.	O

Treatment	O
with	O
2ccPA	O
reduced	O
infiltration	O
of	O
mononuclear	O
cells	O
(	O
Fig	O
.	O
6e	O
).	O

Treatment	O
with	O
2ccPA	O
suppressed	O
sustained	O
scores	O
for	O
inflammation	O
in	O
the	O
spinal	O
cord	O
(	O
Fig	O
.	O
6f	O
).	O
Fig	O
.	O
62ccPA	O
-	O
ameliorated	O
EAE	B-DS
pathological	O
condition	O
and	O
immunopathology	O
.	O

Mice	B-OG
treated	O
with	O
EAE	B-DS
+	O
saline	O
and	O
EAE	B-DS
+	O
2ccPA	O
were	O
immunized	O
with	O
the	O
MOG35	O
−	O
55	O
peptide	O
and	O
clinical	O
scores	O
were	O
assessed	O
daily	O
for	O
30	O
days	O
(	O
a	O
).	O

Treatment	O
with	O
2ccPA	O
after	O
the	O
peak	O
of	O
EAE	B-DS
symptoms	O
had	O
occurred	O
(	O
b	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
5	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
two	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Mann	O
-	O
Whitney	O
U	O
test	O
regarding	O
day	O
0	O
–	O
30	O
(	O
a	O
)	O
or	O
day	O
17	O
–	O
30	O
(	O
b	O
),	O
respectively	O
,	O
(**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
EAE	B-DS
+	O
saline	O
).	O

H	O
&	O
E	O
staining	O
revealed	O
histological	O
features	O
of	O
MOG35	O
−	O
55	O
-	O
induced	O
EAE	B-DS
.	O

Control	O
(	O
c	O
),	O
EAE	B-DS
+	O
saline	O
(	O
d	O
),	O
EAE	B-DS
+	O
2ccPA	O
(	O
e	O
).	O

The	O
degrees	O
of	O
inflammation	O
(	O
f	O
).	O
Scale	O
bar	O
=	O
50	O
μm	O
.	O

Immunostaining	O
with	O
T	O
cell	O
and	O
macrophage	O
infiltration	O
in	O
the	O
spinal	O
cord	O
.	O

Fluorescence	O
for	O
CD4	B-GP
,	O
DAPI	O
,	O
and	O
marge	O
images	O
.	O

Control	O
(	O
g	O
),	O
EAE	B-DS
+	O
saline	O
(	O
h	O
),	O
EAE	B-DS
+	O
2ccPA	O
(	O
i	O
).	O

Number	O
of	O
infiltrating	O
T	O
cells	O
in	O
the	O
spinal	O
cord	O
(	O
m	O
).	O

Fluorescence	O
for	O
F4	O
/	O
80	O
,	O
DAPI	O
,	O
and	O
marge	O
images	O
.	O

Control	O
(	O
j	O
),	O
EAE	B-DS
+	O
saline	O
(	O
k	O
),	O
EAE	B-DS
+	O
2ccPA	O
(	O
l	O
).	O

Number	O
of	O
infiltrating	O
macrophages	O
in	O
the	O
spinal	O
cord	O
(	O
n	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
5	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
#	O
p	O
<	O
0	O
.	O
05	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
EAE	B-DS
+	O
saline	O
).	O
Scale	O
bar	O
=	O
100	O
μm	O

2ccPA	O
suppressed	O
CD4	B-GP
-	O
or	O
F4	O
/	O
80	O
-	O
positive	O
T	O
cell	O
and	O
macrophage	O
infiltration	O
in	O
the	O
spinal	O
cord	O

Infiltration	O
of	O
immune	O
cells	O
(	O
T	O
cells	O
and	O
macrophages	O
)	O
was	O
observed	O
in	O
mice	B-OG
exposed	O
to	O
EAE	B-DS
,	O
although	O
these	O
increases	O
were	O
suppressed	O
following	O
2ccPA	O
administration	O
.	O

Immunofluorescence	O
in	O
the	O
spinal	O
cord	O
was	O
evaluated	O
using	O
the	O
T	O
cell	O
marker	O
CD4	B-GP
and	O
macrophage	O
marker	O
F4	O
/	O
80	O
.	O

In	O
control	O
mice	B-OG
,	O
CD4	B-GP
-	O
and	O
F4	O
/	O
80	O
-	O
positive	O
cells	O
were	O
sporadically	O
distributed	O
in	O
the	O
spinal	O
cord	O
(	O
Fig	O
.	O
6g	O
,	O
j	O
),	O
while	O
an	O
accumulation	O
of	O
infiltrative	O
cells	O
was	O
observed	O
in	O
meningeal	O
area	O
of	O
the	O
spinal	O
cord	O
in	O
mice	B-OG
exposed	O
to	O
EAE	B-DS
(	O
Fig	O
.	O
6h	O
,	O
k	O
).	O

Mice	B-OG
exposed	O
to	O
EAE	B-DS
exhibited	O
T	O
cell	O
and	O
macrophage	O
infiltration	O
,	O
although	O
such	O
infiltration	O
was	O
suppressed	O
by	O
2ccPA	O
treatment	O
(	O
Fig	O
.	O
6i	O
,	O
l	O
).	O

Therefore	O
,	O
treatment	O
with	O
2ccPA	O
effectively	O
suppressed	O
EAE	B-DS
-	O
induced	O
T	O
cell	O
and	O
macrophage	O
infiltration	O
in	O
the	O
spinal	O
cord	O
(	O
Fig	O
.	O
6m	O
,	O
n	O
).	O

Discussion	O

Multiple	B-DS
sclerosis	I-DS
is	O
a	O
heterogeneous	O
disease	O
in	O
clinical	O
presentation	O
,	O
in	O
terms	O
of	O
demyelinating	O
lesions	O
,	O
immunopathological	O
subtypes	O
,	O
response	O
to	O
therapy	O
,	O
and	O
genetic	O
associations	O
[	O
6	O
,	O
32	O
].	O

A	O
detailed	O
immunopathological	O
investigation	O
of	O
demyelinating	O
lesions	O
revealed	O
four	O
distinct	O
immunopathological	O
patterns	O
[	O
6	O
].	O

In	O
patterns	O
I	O
and	O
II	O
,	O
demyelination	B-DS
occurs	O
as	O
a	O
consequence	O
of	O
an	O
autoimmune	O
reaction	O
against	O
myelin	O
,	O
whereas	O
demyelination	B-DS
is	O
independent	O
of	O
immune	O
activation	O
and	O
is	O
caused	O
by	O
oligodendrocyte	O
primary	O
cell	O
loss	O
in	O
patterns	O
III	O
and	O
IV	O
.	O

Previous	O
studies	O
have	O
revealed	O
that	O
administration	O
of	O
EAE	B-DS
and	O
cuprizone	O
reproduces	O
the	O
pathology	O
observed	O
in	O
patterns	O
I	O
/	O
II	O
and	O
patterns	O
III	O
/	O
IV	O
,	O
respectively	O
[	O
33	O
].	O

These	O
animal	B-OG
models	O
accurately	O
represent	O
all	O
aspects	O
of	O
the	O
pathology	O
and	O
clinical	O
features	O
of	O
human	B-OG
multiple	B-DS
sclerosis	I-DS
[	O
34	O
].	O

The	O
findings	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
treatment	O
with	O
2ccPA	O
improved	O
cuprizone	O
-	O
induced	O
motor	O
dysfunction	O
and	O
pathological	O
EAE	B-DS
scores	O
,	O
suggesting	O
that	O
2ccPA	O
may	O
exert	O
beneficial	O
effects	O
in	O
all	O
subtypes	O
of	O
human	B-OG
multiple	B-DS
sclerosis	I-DS
.	O

Neuroinflammation	O
(	O
e	O
.	O
g	O
.,	O
lymphocyte	O
/	O
macrophage	O
infiltration	O
,	O
microglial	O
activation	O
,	O
enhanced	O
cytokine	B-GP
/	O
chemokine	B-GP
production	O
,	O
demyelination	B-DS
,	O
and	O
axonal	O
damage	O
[	O
35	O
–	O
37	O
])	O
is	O
a	O
key	O
component	O
of	O
the	O
pathological	O
progression	O
of	O
all	O
subtypes	O
of	O
multiple	B-DS
sclerosis	I-DS
and	O
in	O
both	O
the	O
EAE	B-DS
and	O
cuprizone	O
models	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
demonstrated	O
that	O
2ccPA	O
suppressed	O
neuroinflammation	O
in	O
the	O
EAE	B-DS
and	O
cuprizone	O
models	O
.	O

2ccPA	O
treatment	O
suppressed	O
the	O
infiltration	O
of	O
CD4	B-GP
-	O
positive	O
T	O
cells	O
and	O
F4	O
/	O
80	O
-	O
positive	O
macrophages	O
to	O
the	O
spinal	O
cord	O
in	O
EAE	B-DS
model	O
mice	B-OG
.	O

CD4	B-GP
-	O
positive	O
T	O
cells	O
secrete	O
proinflammatory	O
cytokines	B-GP
,	O
which	O
play	O
important	O
roles	O
in	O
the	O
neuroinflammatory	O
,	O
cascade	O
,	O
and	O
mediate	O
the	O
damage	O
to	O
the	O
myelin	O
sheath	O
,	O
demyelination	B-DS
,	O
and	O
eventually	O
damage	O
to	O
the	O
neuronal	O
axon	O
[	O
38	O
,	O
39	O
].	O

F4	O
/	O
80	O
-	O
positive	O
microglia	O
/	O
macrophages	O
produce	O
and	O
respond	O
to	O
a	O
wide	O
variety	O
of	O
cytokines	B-GP
,	O
impair	O
blood	O
-	O
brain	O
barrier	O
function	O
,	O
act	O
as	O
antigen	O
-	O
presenting	O
cells	O
within	O
the	O
CNS	O
,	O
mediate	O
phagocytic	O
events	O
,	O
and	O
damage	O
oligodendrocytes	O
[	O
40	O
,	O
41	O
].	O

Therefore	O
,	O
our	O
data	O
suggest	O
that	O
inhibition	O
of	O
T	O
cells	O
and	O
macrophage	O
infiltrates	O
into	O
CNS	O
by	O
2ccPA	O
treatment	O
should	O
be	O
associated	O
with	O
suppression	O
of	O
neuroinflammation	O
in	O
EAE	B-DS
.	O

Further	O
,	O
we	O
also	O
demonstrated	O
that	O
2ccPA	O
suppressed	O
cuprizone	O
-	O
induced	O
microglial	O
activation	O
and	O
NLRP3	B-GP
inflammasome	O
formation	O
.	O

Previous	O
studies	O
have	O
reported	O
that	O
demyelination	B-DS
occurs	O
in	O
parallel	O
with	O
microglial	O
activation	O
in	O
the	O
cuprizone	O
model	O
[	O
9	O
].	O

Activated	O
microglia	O
contribute	O
to	O
the	O
death	O
of	O
oligodendrocytes	O
by	O
secreting	O
proinflammatory	O
cytokines	B-GP
[	O
42	O
]	O
and	O
to	O
axonal	O
damage	O
[	O
43	O
]	O
by	O
stripping	O
synaptic	O
proteins	O
[	O
44	O
].	O

The	O
NLRP3	B-GP
inflammasome	O
signaling	O
pathway	O
is	O
involved	O
in	O
various	O
neuroinflammatory	O
diseases	O
,	O
including	O
multiple	B-DS
sclerosis	I-DS
and	O
the	O
EAE	B-DS
and	O
cuprizone	O
models	O
.	O

Activation	O
of	O
the	O
P2X7	B-GP
receptor	I-GP
,	O
principally	O
by	O
extracellular	O
ATP	O
,	O
induces	O
NLRP3	B-GP
inflammasome	O
activation	O
and	O
promotes	O
the	O
processing	O
and	O
release	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
.	O

IL	B-GP
-	I-GP
1β	I-GP
is	O
a	O
pivotal	O
mediator	O
in	O
the	O
neuroinflammatory	O
response	O
[	O
9	O
]	O
and	O
promotes	O
leukocyte	O
infiltration	O
by	O
inducing	O
the	O
expression	O
of	O
many	O
cytokines	B-GP
,	O
chemokines	B-GP
,	O
and	O
adhesion	O
molecules	O
.	O

A	O
recent	O
study	O
has	O
reported	O
that	O
microglia	O
express	O
the	O
NLRP3	B-GP
inflammasome	O
and	O
release	O
IL	B-GP
-	I-GP
1β	I-GP
[	O
45	O
],	O
suggesting	O
that	O
the	O
microglial	O
NLRP3	B-GP
inflammasome	O
probably	O
promotes	O
CNS	O
inflammation	O
and	O
demyelination	B-DS
.	O

In	O
our	O
study	O
,	O
2ccPA	O
suppressed	O
cuprizone	O
-	O
induced	O
microglial	O
activation	O
and	O
NLRP3	B-GP
inflammasome	O
,	O
suggesting	O
that	O
2ccPA	O
suppressed	O
the	O
neuroinflammation	O
to	O
inhibit	O
the	O
microglial	O
NLRP3	B-GP
inflammasome	O
caused	O
by	O
excessive	O
microglial	O
activation	O
.	O

Microglia	O
are	O
known	O
to	O
develop	O
diverse	O
functional	O
phenotypes	O
of	O
proinflammatory	O
(	O
M1	O
)	O
and	O
alternative	O
(	O
M2	O
)	O
activation	O
[	O
46	O
,	O
47	O
].	O

Previous	O
findings	O
have	O
revealed	O
that	O
NLRP3	B-GP
promotes	O
microglial	O
M1	O
activation	O
and	O
that	O
the	O
NLRP3	B-GP
complex	O
is	O
contained	O
in	O
M1	O
microglia	O
[	O
48	O
].	O

In	O
the	O
present	O
study	O
,	O
2ccPA	O
treatment	O
suppressed	O
markers	O
of	O
the	O
NLRP3	B-GP
inflammasome	O
(	O
NLRP3	B-GP
,	O
P2X7	B-GP
,	O
and	O
IL	B-GP
-	I-GP
1b	I-GP
)	O
but	O
not	O
of	O
M2	O
microglia	O
(	O
Arg1	B-GP
,	O
Fizz1	B-GP
,	O
and	O
Ym1	B-GP
),	O
suggested	O
that	O
2ccPA	O
suppressed	O
the	O
microglial	O
M1	O
proinflammatory	O
activation	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
2ccPA	O
improves	O
the	O
pathological	O
state	O
of	O
EAE	B-DS
and	O
cuprizone	O
model	O
mice	B-OG
by	O
mediating	O
the	O
attenuation	O
of	O
neuroinflammatory	O
conditions	O
(	O
i	O
.	O
e	O
.,	O
infiltration	O
of	O
immune	O
cells	O
and	O
microglial	O
NLRP3	B-GP
inflammasome	O
,	O
respectively	O
).	O

Under	O
neuroinflammatory	O
conditions	O
,	O
mitochondrial	O
apoptotic	O
cell	O
death	O
has	O
been	O
observed	O
following	O
damage	O
to	O
the	O
CNS	O
[	O
49	O
].	O

Mitochondrial	O
dysfunction	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
loss	O
of	O
oligodendrocytes	O
and	O
neuronal	O
axons	O
in	O
multiple	B-DS
sclerosis	I-DS
[	O
50	O
]	O
and	O
in	O
the	O
EAE	B-DS
and	O
cuprizone	O
models	O
.	O

The	O
mitochondria	O
-	O
mediated	O
apoptosis	O
pathway	O
is	O
largely	O
controlled	O
by	O
the	O
master	O
apoptosis	O
inducer	O
Bax	B-GP
and	O
the	O
apoptosis	O
suppressor	O
Bcl	B-GP
-	I-GP
2	I-GP
[	O
51	O
].	O

Phosphorylation	O
and	O
activation	O
of	O
JNK	B-GP
and	O
p38MAPK	B-GP
also	O
promote	O
mitochondrial	O
apoptotic	O
cell	O
death	O
[	O
52	O
,	O
53	O
].	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
2ccPA	O
suppressed	O
CoCl2	O
-	O
induced	O
apoptosis	O
.	O

We	O
reported	O
previously	O
that	O
natural	O
cPA	O
suppressed	O
mitochondrial	O
apoptosis	O
of	O
neuronal	O
cells	O
in	O
vitro	O
and	O
delayed	O
neuronal	O
death	O
in	O
vivo	O
.	O

Therefore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
protective	O
function	O
of	O
2ccPA	O
suppressed	O
the	O
mitochondrial	O
apoptosis	O
pathway	O
in	O
both	O
oligodendrocytes	O
and	O
neurons	O
,	O
which	O
is	O
likely	O
to	O
be	O
associated	O
with	O
protection	O
from	O
the	O
loss	O
of	O
oligodendrocytes	O
and	O
axons	O
in	O
demyelinative	O
conditions	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
2ccPA	O
promotes	O
neurite	O
outgrowth	O
and	O
enhances	O
neuronal	O
survival	O
via	O
a	O
signaling	O
pathway	O
similar	O
to	O
that	O
of	O
NGF	B-GP
[	O
11	O
].	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
2ccPA	O
exerts	O
protective	O
effects	O
against	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
and	O
EAE	B-DS
pathology	O
via	O
NGF	B-GP
-	O
like	O
actions	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
NGF	B-GP
exerts	O
a	O
dramatic	O
effect	O
on	O
neuron	O
and	O
oligodendrocyte	O
survival	O
and	O
stimulates	O
axonal	O
regeneration	O
/	O
remyelination	O
[	O
54	O
,	O
55	O
].	O

These	O
findings	O
are	O
in	O
accordance	O
with	O
the	O
protective	O
effects	O
against	O
CPZ	O
-	O
induced	O
demyelination	B-DS
observed	O
in	O
our	O
study	O
.	O

Additional	O
studies	O
have	O
indicated	O
that	O
NGF	B-GP
may	O
exert	O
protective	O
effects	O
in	O
EAE	B-DS
model	O
mice	B-OG
by	O
switching	O
the	O
immune	O
response	O
to	O
an	O
anti	O
-	O
inflammatory	O
status	O
[	O
56	O
,	O
57	O
].	O

Indeed	O
,	O
our	O
findings	O
indicate	O
that	O
a	O
similar	O
process	O
may	O
underlie	O
the	O
protective	O
effect	O
of	O
2ccPA	O
against	O
EAE	B-DS
.	O

Furthermore	O
,	O
NGF	B-GP
is	O
a	O
potent	O
anti	O
-	O
apoptotic	O
factor	O
that	O
regulates	O
levels	O
of	O
anti	O
-	O
apoptotic	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	O
,	O
a	O
common	O
mechanism	O
by	O
which	O
2ccPA	O
protected	O
oligodendrocytes	O
from	O
CoCl2	O
-	O
induced	O
apoptosis	O
[	O
58	O
].	O

These	O
findings	O
suggest	O
that	O
multiple	O
effects	O
of	O
2ccPA	O
are	O
due	O
to	O
its	O
NGF	B-GP
-	O
like	O
actions	O
.	O

There	O
is	O
a	O
need	O
for	O
therapeutic	O
drug	O
treatment	O
of	O
progressive	B-DS
multiple	I-DS
sclerosis	I-DS
that	O
can	O
arrest	O
the	O
progression	O
of	O
demyelination	B-DS
.	O

Our	O
results	O
may	O
indicate	O
that	O
2ccPA	O
has	O
a	O
beneficial	O
effect	O
on	O
progressive	O
demyelination	B-DS
.	O

Treatment	O
with	O
2ccPA	O
suppressed	O
demyelination	B-DS
and	O
motor	O
dysfunction	O
even	O
after	O
the	O
onset	O
of	O
cuprizone	O
-	O
induced	O
pathology	O
(	O
protocol	O
B	O
and	O
D	O
).	O

Further	O
,	O
2ccPA	O
might	O
have	O
a	O
function	O
to	O
enhance	O
remyelination	O
(	O
protocol	O
C	O
).	O

In	O
summary	O
,	O
we	O
found	O
that	O
the	O
administration	O
of	O
2ccPA	O
reduced	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
,	O
microglial	O
activation	O
,	O
NLRP3	B-GP
inflammasome	O
,	O
and	O
motor	O
dysfunction	O
,	O
and	O
promoted	O
remyelination	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
2ccPA	O
reduced	O
autoreactive	O
T	O
cell	O
and	O
macrophage	O
,	O
spinal	B-DS
cord	I-DS
injury	I-DS
,	O
and	O
clinical	O
behavioral	O
dysfunction	O
in	O
the	O
autoimmune	O
multiple	B-DS
sclerosis	I-DS
model	O
of	O
EAE	B-DS
.	O

These	O
data	O
indicate	O
that	O
2ccPA	O
may	O
be	O
a	O
promising	O
seed	O
compound	O
for	O
the	O
development	O
of	O
new	O
drugs	O
to	O
treat	O
demyelinating	B-DS
disease	I-DS
and	O
ameliorate	O
the	O
symptoms	O
of	O
multiple	B-DS
sclerosis	I-DS
.	O

Conclusions	O

The	O
findings	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
2ccPA	O
protected	O
oligodendrocytes	O
via	O
suppression	O
of	O
the	O
mitochondrial	O
apoptosis	O
pathway	O
.	O

Beneficial	O
effects	O
of	O
2ccPA	O
were	O
observed	O
in	O
the	O
multiperiod	O
of	O
cuprizone	O
-	O
induced	O
demyelination	B-DS
and	O
EAE	B-DS
pathology	O
.	O

These	O
data	O
indicate	O
that	O
2ccPA	O
is	O
a	O
promising	O
candidate	O
for	O
the	O
development	O
of	O
new	O
drugs	O
for	O
the	O
treatment	O
of	O
demyelinating	O
conditions	O
such	O
as	O
multiple	B-DS
sclerosis	I-DS
.	O

